# US 9,434,768 B2 · Viruses lacking epithelial cell receptor entry

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,434,768 B2
- Document ID: US9434768B2
- Status: Granted
- Kind: B2
- Application number: 14/249,821
- Filed: 2014-04-10
- Published: 2014-08-21
- Granted: 2016-09-06
- Earliest claimed: 2008-03-21
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Roberto Cattaneo; Vincent H. J. Leonard
- Web page: https://patentgrep.com/patent/US9434768B2

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/165: Mumps or measles virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 2039/5254: {avirulent or attenuated}
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 15/09: Recombinant DNA-technology
- C12N 2760/18422: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18461: Methods of inactivation or attenuation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The document provides nucleic acids, polypeptides, and viruses containing nucleic acids and/or polypeptides. The document also provides methods for using viruses to treat cancer patients. Specifically, the document provides nucleic acid molecules encoding viral hemagglutinin (H) polypeptides, viral H polypeptides, and viruses containing nucleic acids and/or H polypeptides. Such viruses are useful for vaccinations and for treating cancer patients as the viruses are not shed.

## Claims

### Claim 1

An isolated nucleic acid molecule, wherein said nucleic acid molecule encodes a polypeptide comprising a hemagglutinin (H) polypeptide amino acid sequence that aligns with and has at least 85 percent identity to the amino acid sequence set forth in SEQ ID NO: 1, wherein said H amino acid sequence comprises an amino acid other than leucine at the position aligning with position 482 of said amino acid sequence, wherein said amino acid other than leucine is serine.

### Claim 2 (depends on 1)

The isolated nucleic acid of claim 1, wherein said H polypeptide amino acid sequence further comprises an amino acid other than proline at the position aligning with position 497 of said amino acid sequence or an amino acid other than tyrosine at the position aligning with position 543 of said amino acid sequence.

### Claim 3 (depends on 2)

The isolated nucleic acid of claim 2, wherein said H polypeptide amino acid sequence further comprises a serine at the position aligning with position 497 of said amino acid sequence.

### Claim 4 (depends on 2)

The isolated nucleic acid of claim 2, wherein said H polypeptide amino acid sequence further comprises an alanine at the position aligning with position 543 of said amino acid sequence.

### Claim 5 (depends on 2)

The isolated nucleic acid of claim 2, wherein said H polypeptide amino acid sequence further comprises a serine at the position aligning with position 497 of said amino acid sequence and an alanine at the position aligning with position 543 of said amino acid sequence.

### Claim 6 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule further encodes an F polypeptide.

### Claim 7 (depends on 1)

A cell comprising the isolated nucleic acid molecule of claim 1.

### Claim 8 (depends on 7)

The cell of claim 7, wherein said cell is a cell line or a primary cell, wherein said cell line is selected from the group consisting of a Vero cell line, a Vero/hSLAM cell line, and a Jurkat cell line, wherein said primary cell is selected from the group consisting of B lymphocytes, T lymphocytes, dendritic cells, macrophages, and cells from resected primary tumors.

### Claim 9 (depends on 1)

A virus comprising the isolated nucleic acid molecule of claim 1.

### Claim 10 (depends on 9)

The virus of claim 9, wherein said virus is selected from the group consisting of a measles virus, a canine distemper virus, and a rinderpest virus.

### Claim 11 (depends on 10)

The virus of claim 10, wherein said virus is a measles virus.

### Claim 12 (depends on 11)

The virus of claim 11, wherein said measles virus is a vaccine strain.